María Agustina Perusini
YOU?
Author Swipe
View article: New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients
New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Open
Tyrosine kinase inhibitors (TKIs) significantly improved outcomes for patients with chronic myeloid leukemia (CML), enabling optimal treatment responses and near-normal life expectancy. Despite optimal responses, clonal evolution (CE) in P…
View article: Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis
Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis Open
View article: Olverembatinib in chronic myeloid leukemia: is less actually better?
Olverembatinib in chronic myeloid leukemia: is less actually better? Open
Not available.
View article: Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with <i>BCR</i>::<i>ABL1</i> digital <scp>PCR</scp> in chronic myeloid leukemia patients
Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with <i>BCR</i>::<i>ABL1</i> digital <span>PCR</span> in chronic myeloid leukemia patients Open
Precise and reliable predictive parameters to accurately identify chronic myeloid leukemia (CML) patients who can successfully discontinue their tyrosine kinase inhibitor (TKI) treatment are lacking. One promising parameter is depth of mol…
View article: Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase
Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase Open
This retrospective report presents the outcomes and adverse events (AEs) observed in 73 patients aged 60 years or older diagnosed with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (Ph-negative ALL) treated with a pediatric…
View article: Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes Open
Advancements in genomics are transforming the clinical management of chronic myeloid leukemia (CML) toward precision medicine. The impact of somatic mutations on treatment outcomes is still under debate. We studied the association of somat…
View article: Somatic mutations in myeloid transcription factors and in activated signaling genes predict the risk of treatment failure and progression to advanced phase in chronic myeloid leukemia
Somatic mutations in myeloid transcription factors and in activated signaling genes predict the risk of treatment failure and progression to advanced phase in chronic myeloid leukemia Open
Background Advancements in genomics are transforming the clinical management of chronic myeloid leukemia (CML) towards precision medicine. The impact of epigenetic modifier gene mutations on treatment outcomes is still under debate. Here w…
View article: P385: COMPARISON OF CLINICAL OUTCOMES AND ADVERSE EVENTS IN OLDER ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH NATIVE VS PEGYLATED ASPARAGINASE
P385: COMPARISON OF CLINICAL OUTCOMES AND ADVERSE EVENTS IN OLDER ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH NATIVE VS PEGYLATED ASPARAGINASE Open
Background: Poor outcomes in older patients with acute lymphoblastic leukemia (ALL) result from the disease’s adverse biology and poor tolerance to chemotherapy due to organ dysfunction, frailty, and performance status. Pediatric-inspired …
View article: Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report
Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report Open
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. It is associated with poor prognosis and heterogenous presentation. The CD123‐directed cytotoxin, Tagraxofusp, is a targeted therapy for …
View article: Decrease in Mortality from Sepsis: Impact of the Multidisciplinary Program for the Hematologic Patient at Very High Risk
Decrease in Mortality from Sepsis: Impact of the Multidisciplinary Program for the Hematologic Patient at Very High Risk Open
View article: Severe thrombocytopenia as a predictor of survival and response to hypomethylating agents in myelodysplastic syndromes: A <scp>Latin‐American</scp> cohort of 212 patients
Severe thrombocytopenia as a predictor of survival and response to hypomethylating agents in myelodysplastic syndromes: A <span>Latin‐American</span> cohort of 212 patients Open
Severe thrombocytopenia is a challenging situation in the treatment of myelodysplastic syndromes (MDS), with profound implications for prognosis and treatment decisions. The limit of 3.5). At treatment initiation, Hb level < 8 g/dL, absol…
View article: PB2226 PHILADELPHIA‐NEGATIVE MYELOPROLIFERATIVE NEOPLASMS, CLINICAL MANIFESTATION AND OUTCOME. EXPERIENCE AT HOSPITAL ITALIANO DE BUENOS AIRES
PB2226 PHILADELPHIA‐NEGATIVE MYELOPROLIFERATIVE NEOPLASMS, CLINICAL MANIFESTATION AND OUTCOME. EXPERIENCE AT HOSPITAL ITALIANO DE BUENOS AIRES Open
Background: BCR‐ABL negative myeloproliferative neoplasms(MPNs) are a heterogeneous group of clonal hematopoietic disorders including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF) and prefibrotic primar…